Biotechnology
Cancer
Treatment
United
States
Stock
Offering
Warrants
M&A Advisory
Lazard
Full Credential Description
OXiGENE. United States. Announced Date 15/07/2009. Closed Date 20/07/2009. Deal value: $10m. Registered direct offering of common stock and warrants. Industry: OXiGENE is a biotechnology company focused on developing therapeutics for cancer treatment.